Portfolio

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

The Aralez portfolio of approved and investigational products is anchored in cardiovascular disease therapies, with a significant pain treatment franchise, and plans for continued development and growth in these and other specialty areas.

Cardiovascular

Product Status Territories

Marketed

Marketed

Marketed

Marketed

Marketed

Marketed

Marketed

Pain/Inflammation

Product Status Territories

Marketed

Marketed

Marketed

Marketed

Investigational

Marketed

Marketed*

Marketed

Marketed*

* Treximet is marketed by Pernix in the U.S.
* VIMOVO is marketed by Horizon Pharma in the U.S. and AstraZeneca ex – U.S.

Other Products

DERMATOLOGY

Product Status Territories

Marketed

Marketed

GASTROINTESTINAL
NONPRESCRIPTION PRODUCTS

Product Status Territories

Marketed

Marketed

Marketed

Marketed

Marketed

Marketed

Marketed

Marketed

OTHER
NONPRESCRIPTION PRODUCTS

Product Status Territories

Marketed

Marketed

Marketed

WOMEN’S HEALTH
NONPRESCRIPTION PRODUCTS

Product Status Territories

Marketed

Rest of the world